Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Revlar

Bristol-Myers Squibb (BMS) building

BMS claims 80% market share for Opdivo in US

New indications and label updates boost the cancer immunotherapy’s market position

- PMLiVE

AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

Continues to build its oncology business to lessen its reliance on Humira

- PMLiVE

Respiratory return helps GSK to solid first quarter

Seretide decline offset by gains for new-generation products Anoro, Breo and Nucala

- PMLiVE

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

EAGLES trial of 8,000 patients backs the smoking cessation drugs' safety

- PMLiVE

GSK’s morality gene

The firm is mutating in important ways - we should watch carefully

Boehringer to target COPD adherence

Partners with Propeller Health on digital health deal

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

- PMLiVE

GSK unveils access plan for low-income countries

Will file patents for its drugs according to each country’s 'economic maturity'

- PMLiVE

Japanese approvals for GSK, AZ and Bayer

MHLW gives Nucala, Tagrisso and Xofigo the green light

- PMLiVE

Genital herpes vaccine candidate promising in phase II

Genocea Biosciences’ GEN-003 found to reduce recurrence and transmission of the virus

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

- PMLiVE

UK government fines GSK over ‘pay-for-delay’ deals

Merck KGaA and Actavis also fined for their involvement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links